Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

22.41USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$22.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
134,446
52-wk High
$41.24
52-wk Low
$20.25

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.95
Market Cap(Mil.): $589.52
Shares Outstanding(Mil.): 26.15
Dividend: --
Yield (%): --

Financials

  LJPC.OQ Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -7.17 -- --
ROI: -85.25 3.31 12.77
ROE: -138.56 2.31 14.92

BRIEF-La Jolla Pharmaceutical Co Announces $125 Mln Royalty Financing Agreement With Healthcare Royalty Partners

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $125 MILLION ROYALTY FINANCING AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-La Jolla Pharmaceutical Quarterly Loss Per Share $2.22

* LA JOLLA PHARMACEUTICAL ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2018 AND RECENT CORPORATE PROGRESS

May 10 2018

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

Mar 22 2018

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

Mar 15 2018

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 14 2018

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

Feb 22 2018

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

Feb 21 2018

Competitors

Earnings vs. Estimates